Insider Selling: TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Sells $951,885.08 in Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

TScan Therapeutics Price Performance

NASDAQ:TCRX opened at $5.64 on Friday. TScan Therapeutics, Inc. has a 52-week low of $2.14 and a 52-week high of $9.69. The company has a market cap of $298.75 million, a P/E ratio of -4.41 and a beta of 0.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. The stock’s 50-day simple moving average is $6.30 and its 200 day simple moving average is $7.17.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. As a group, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Analysts Set New Price Targets

TCRX has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 13th. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Monday, August 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research note on Monday, August 12th. Finally, BTIG Research began coverage on TScan Therapeutics in a report on Thursday, May 16th. They issued a “buy” rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.00.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Great Point Partners LLC bought a new position in shares of TScan Therapeutics in the 2nd quarter valued at about $5,504,000. Tocqueville Asset Management L.P. acquired a new position in TScan Therapeutics during the first quarter worth approximately $1,685,000. abrdn plc bought a new stake in TScan Therapeutics in the fourth quarter valued at approximately $1,166,000. Bank of Montreal Can acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $749,000. Finally, Bank of New York Mellon Corp bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $682,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.